CClinicalTrials.gg
CompletedNCT04332354CGM-BARIAUpdated Apr 2, 2020

Glycemic Profile by CGMS in Diabetic Patients After Bariatric Surgery

An observational study in Type 2 Diabetes Mellitus in Obese and Bariatric Surgery Candidate, sponsored by University Hospital, Caen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-02.

Sponsored by University Hospital, Caen · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
31
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this observational prospective monocentric study is to examine glycemic patterns in adult T2D patients candidates to bariatric surgery, by using a continuous glucose monitoring (CGM) sensor over 14 days post-surgery, in order to search for indicators predicting T2D remission 1 year after surgery.

Read the detailed description

In this exploratory monocentric study performed at the Caen University Hospital in France, adult T2D patients consecutively enrolled for metabolic surgery will be prospectively included for continuous glucose monitoring (CGM) recordings during the month preceding bariatric surgery and during the 2 weeks following surgery. Changes in body weight will be evaluated using weight measurement, BMI measurement and the percentage of excess weight loss (% EWL), calculated using the formula: initial weight-actual weight/initial weight - (25 x height2). Changes in diabetic status will be evaluated by HbA1c assay and collection of data on anti-diabetic treatment maintained during the follow-up. The Ad-Diarem score for predicting diabetes remission will be calculated in each patient from several variables including age, diabetes duration, insulin use, other glucose-lowering agents used, number of glucose-lowering agents used and HbA1c level. The variables recorded by CGM will include : mean daily interstitial glucose concentration (mg/dL), standard deviation (SD) of glucose concentration (mg/dL), coefficient of variation (CV) of glucose concentration corresponding to the SD-to-mean daily interstitial glucose ratio, time in normoglycemia (ie in the stringent 70-140mg/dL target which better reflects normoglycemia than the 70-180 mg/dl target) or time in range (TIR) as a percentage over 24h, time spent in hyperglycemia (ie >140mg/dL) or time above range (TAR) as a percentage over 24h, and time spent in hypoglycemia (\<70mg/dL) or time below range (TBR) as a percentage over 24h.

Judgement criteria are defined as follows: the success of bariatric surgery will be defined as a % EWL >50%; normalization of glycemia will be defined as a mean 24-hr interstitial glucose level \<100mg/d during the CGM recording period; diabetes remission after metabolic surgery will be defined as an HbA1c level at 1 year after surgery of \< 6.0% without the use of any glucose-lowering agent. Such thresholds were chosen to meet the definition of complete remission by the American Society for Metabolic and Bariatric Surgery and the American Diabetes Association.

Quantitative variables will be expressed as mean + standard deviation. Qualitative variables will be expressed as percentages. Differences in quantitative variables, when compared to the pre-operative period, will be examined using Students t-test for paired data or with ANOVA. Analysis of subgroups will be carried out using Chi-2 test. Identification of predictive factors for diabetes remission will be based on analysis of ROC curves and the calculation of area under the curve data, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative likelihood ratio (LR+ and LR-) at different thresholds for each study variable including the pre-operative and post-operative CGM variables and the Add-Diarem score.

02

Conditions studied

  • Type 2 Diabetes Mellitus in Obese
  • Bariatric Surgery Candidate

Keywords

  • continuous glucose monitoring
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's enrollment of 31 is below the median of 300 across 1,588 observational studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

University Hospital, Caen is the lead sponsor of 505 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

T2D, obesity (BMI>35), candidates for metabolic surgery oral or injectable anti diabetic treatments including insulin injections or pump therapy

Inclusion criteria

  • type 2 diabetes and obesity (BMI> 35)
  • treated with oral anti-diabetic medication and/or insulin therapy
  • candidate for bariatric surgery

Exclusion criteria

Exclusion Criteria:

  • refusal of CGM recordings
  • refusal of bariatric surgery
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
31 participants (actual)
Patient registry
No

Groups and cohorts

  • T2D diabetes obese subjects

    Patients have T2D diabetes and are candidates for bariatric surgery. They will receive routine cares and follow-up and will have CGM measurement before and 2 weeks following the surgery

    Other: routine care. No intervention

Interventions

  • Otherroutine care. No intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. glycemic profile after bariatric surgery

    CGM recordings 4-14 days of the immediate postoperative period

    Time frame: 4-14 days recordings

Secondary outcomes

  1. glycemic profile before bariatric surgery

    CGM recordings before bariatric surgery

    Time frame: 5 days recordings

  2. identification of predictive factors for diabetes remission 1 year after surgery

    CGM variables and Add-Diarem score

    Time frame: 5 days recordings for CGM

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04332354
Lead sponsor
University Hospital, Caen
Responsible party
Sponsor
First posted
Apr 2, 2020
Start date
Mar 30, 2016
Primary completion
Mar 30, 2018
Completion
May 30, 2018
Last update
Apr 2, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion